Recent

% | $
Quotes you view appear here for quick access.

Enzo Biochem Inc. Message Board

surfer_bj 26 posts  |  Last Activity: Aug 6, 2015 2:00 PM Member since: Sep 28, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • brokerage presently has a $13.00 price on the stock. Craig Hallum’s target price suggests a potential upside of 41.30%

    Sentiment: Buy

  • Cash and cash equivalents at end of period $210,035! Total stockholders’ equity 2015 $283,103
    2014 $276,888. Total revenue increased to $55.9 million compared to $51.7 million a year ago.

    -- Revenue from media and advertising increased 14% compared to a year ago.

    -- Adjusted EBITDA was $4.6 million compared to $3.7 million a year ago.

    GAAP net loss for the second quarter 2015 was $9.3 million, which included $8.5 million in stock-based compensation expense and $2.1 million in change in fair value of contingent consideration expense related to our acquisition of Eckim. GAAP net loss in the second quarter of 2014 was $6.9 million, which included $6.7 million in stock-based compensation expense.

    -- Cash generated from operations was $6.9 million compared to $5.2 million in the same period last year.

    -- Total digital coupon transactions during the second quarter were 372 million compared to 384 million in second quarter 2014.

    Digital coupon transaction volumes through Retailer iQ increased almost 70% in the first half of 2015 as compared to the second half of 2014.
    Growth in media:

    -- Our media and advertising business grew 14% year over year


    Looks like you need to sell your garbage. In reality, company did better than 2014 and meet their revenues. Revenues to grow 2015 along with new business/products/ads/coupons/retailers etc.. Coup stock moved from $14 to $9 following sector underperformance. Looks like Coup has overly paid for its peers.....

    I'd say time to buy when the sector in down....as overdone.... Looks like you need to sell your garbage.

    Sentiment: Buy

  • surfer_bj surfer_bj Aug 5, 2015 3:32 PM Flag

    Last quarterly expecting positive forward.....Coup is in sector that was hit with negative earnings from SALE and Twtr etc. Coup meets or surprise, they will be fine. This follow the sector thing is way over done in my view....Sale down 38% today....Coup has a different business and is expanding it forward....

    Sentiment: Strong Buy

  • Reply to

    Dilution

    by kdawg2sweet Jul 29, 2015 8:42 AM
    surfer_bj surfer_bj Jul 30, 2015 3:36 PM Flag

    PTX: Yes A Poison Pill Could Be a Reason for new shares or are possibly being used in buying/adding a lot more new products to their pipelines, or both. In a securities filing, Depomed said it has adopted a poison-pill plan that would be triggered by a person or group acquiring a more than 10% stake in the company. A poison pill, or shareholder rights plan, is designed to dilute the value of stock by flooding the market with additional shares, making it more difficult for an investor to acquire a controlling stake.

    Sentiment: Buy

  • Terms of the agreement (PTX NEW SHARES related to Merger ) NOTE Milestones PTX To Receive!
    Under terms of the agreement (as amended), Pernix, through its wholly-owned subsidiary, Ferrimill Limited (“Ferrimill”), has paid Zogenix $70 million in cash, issued to Zogenix 1,682,086 shares of Pernix common stock and deposited an additional $10 million in cash in escrow to fund potential indemnification claims for a period of 12 months following the closing. Pernix has also purchased certain Zohydro ER inventory as part of the transaction.

    Ferrimill has also agreed to make certain payments conditioned on regulatory and commercial milestones of up to $283.5 million, including $12.5 million upon approval of ZX-007, a tablet formulation of extended-release hydrocodone with abuse-deterrent properties, and up to $271 million in potential sales milestones based on the achievement of pre-determined annual product sales milestones for Zohydro ER and ZX-007. Under the terms of the acquisition agreement, over 80% of the value of the sales milestones is tied to the achievement of net sales targets ranging from $500 million to $1 billion.

    Pernix will purchase a pre-defined amount of Zohydro ER product inventory. Pernix will also seek to retain certain employees of Zogenix, including the field sales force of approximately 100 sales professionals and additional personnel related to the brand.

    Jefferies LLC acted as financial advisor to Pernix. The Company’s legal advisers are Lowenstein Sandler LLP and Goodwin Procter LLP. Buchanan Ingersoll & Rooney PC acted as intellectual property counsel.

    Sentiment: Buy

  • Reply to

    JUDAS Priest

    by rja37 Jul 29, 2015 3:58 PM
    surfer_bj surfer_bj Jul 29, 2015 6:35 PM Flag

    Who's to know what management has planned. Shares could be used for future mergers?
    It's called investing for future growth. If the company makes new income from their new purchase, that puts PTX in a positive growth and those extra shares will/could mean future higher income/stock price and so on.

    Look how many outstanding shares other companies have compare to PTX'S 43 M shares. CELG 800 Mil, AMRN 176 M, AMGN 760 M, GILD 1.5 B outstanding shares, etc.. It's all about expanding growing their business. New management has managed to do so in a short time compared to old management.

    Look on the bright side, one can buy these shares while they are cheap...The street has turned itself into a manipulative stock market. Wish we had the old stock market days back before the computer and all the naked shorting. While Bubbles and Recessions have always be around. ...As... they... say, "Don't put all your eggs in one basket"! Having your home and debt paid off is the best investment you can ever make. Stock market should just be considered gambling and risky in this worlds economy. One should only use a small percentage of your savings for stock investing.

    Pernix Therapeutics Inc. to Report Second Quarter 2015 Financial Results On Thursday, August 6, 201

    Sentiment: Buy

  • surfer_bj surfer_bj Jul 16, 2015 8:31 PM Flag

    nvaa2, thanks for the welcome. So many mouthy shorts getting hyper as OHR shows it's true colors and analyst are taking a positive look. Invest in several drug companies and try to keep up on the news and new products. When the street missed OHR'S positive information in May, had to buy. Must be those Wall Street Games they play.
    My opinion from research, Could OHR be used exclusively for some eye conditions without lucentis or any other injectable.
    Lucentis is administered in the form of smaller molecules in its ability to penetrate the eye's retina and halt abnormal blood vessel growth contributing to advanced macular degeneration and scarring that causes blindness.
    “So can OHR’S own formulated drops stop abnormal blood vessel growth and also become a healing drug that works on bringing back the normal vessels?” Having the recent positive vision improvements, is showing us that adding the drops are absorbing faster than just using lucentis alone. Adjusting the dosage higher or lower will come in time once they can demonstrate through a phase III trial.”
    Research:
    The main challenge will be to demonstrate Squalamine's ability to travel to the back of the eye and stay there long enough to be absorbed. "Complete replacement (for injections) is completely unnecessary for Ohr's success," said Aschoff. "Just look at how well Eylea is doing with reduction of injection frequency as its main thrust." Like Eylea a and Lucentis, Squalamine targets a specific protein, VEGF, or vascular endothelial
    growth factor, in order to block the formation and growth of new blood vessels in the eye. It also targets other factors behind blood vessel growth.
    Analyst from 2013 If the results are good, Aschoff said it might eventually make sense for Ohr, which is also developing a treatment for cancer cachexia, a severe wasting disorder, to sell itself or Squalamine to a bigger competitor. "(The acquirer) could buy it to sit on it, and not develop it, to save their injectable franchise," he said. "Or they could buy it to develop it - and see whichever one brings in the most revenue."

    Sentiment: Strong Buy

  • Type Phase III Trials in wet-AMD 11-May-2015 Quarterly Report
    The data from the Phase II clinical trial support the Company conducting Phase III trials for a targeted population, with enrollment criteria to be determined based on a complete analysis of the Phase II clinical trial.

    The positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to increase through the end of the study, supporting the planned Phase III development program for a targeted population.

    At an end of Phase II meeting with the U.S. Food and Drug Administration ("FDA") in September 2014, the FDA agreed with the Company on a 9 month primary efficacy endpoint for the Phase III trials. We anticipate initiating the Phase III clinical trial program in the second half of calendar 2015.
    message

    Sentiment: Strong Buy

  • Reply to

    THE FIRST PAHSE 2 TRIAL FAILED

    by stratusstratus Jul 15, 2015 5:40 PM
    surfer_bj surfer_bj Jul 15, 2015 6:45 PM Flag

    So why would FDA approve a phase III trial if Failed? Prove to me where OHRP stated that 1st phase 2 trial Failed? Appears that fewer injections did not happen but everything else proved to be positive.
    Improved vision vs fewer injections.

    Street made a huge error selling down OHRP stock on injections alone, not viewing positive Vision response.
    CEO 1st phase 2 statement...

    Ohr Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference

    Visual Acuity Benefits Demonstrated in Classic CNV Containing Lesions
    Data Support a Phase III Development Program in an Optimized Wet-AMD Patient Population

    "The results from the IMPACT study demonstrate that topically administered OHR-102 combination therapy can lead to improved visual function in patients with wet AMD and, importantly, that the efficacy results may be determined by lesion size and composition," stated Dr. Jason Slakter, Chief Medical Officer at Ohr. "There was a clear and clinically meaningful benefit in patients whose lesions contained some classic CNV. These data support a Phase III development program in a targeted population which will be based upon a complete analysis of the IMPACT study results. We expect to commence the Phase III development program with OHR-102 combination therapy in the second half of 2015."

    Dr. Slakter also presented the data on patients with classic containing lesions in the intent-to-treat (ITT-LOCF) population (OHR-102 n=38, Lucentis monotherapy n=32). In this group, the mean gains in visual acuity were +10.5 letters for the OHR-102 combination arm and +5.4 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.1 letters. In addition, 42% of the patients receiving OHR-102 achieved a ≥3 line gain at nine months, as compared to 28% in the Lucentis monotherapy group.

    As previously reported, the mean number of injections between the treatment arms over the 9 months of treatment, the primary endpoint of the study, was not meaningfully different.

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jul 14, 2015 7:50 PM Flag

    If you want to see a trial with 2,000 patients, as you stated, than you need a phase III trial....You don't spend millions until you can justify that the drug shows positive improvement and favorable safety as said by CEO.

    The positive results of this Phase II study demonstrates the role of OHR-102 combination therapy in RVO and represent an important milestone for the development of OHR-102 in the treatment of this disease," said Dr. Jason Slakter, Chief Medical Officer of Ohr. "This trial constitutes the second clinical study in a retinal vascular disorder which has shown a positive and clinically meaningful benefit in visual acuity using OHR-102 combination therapy versus an intravitreal anti-VEGF injection alone. The consistency of the efficacy data in this study, combined with the favorable safety profile of OHR-102, we believe warrants further study in a large controlled clinical trial."

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jul 14, 2015 7:42 PM Flag

    Read the news release In my last message. States that this is the 2nd of recent trials showing positive vision gains. Last phase II Clinical Study had about 120 patients. See Below part of news yesterdays news.

    Last trial Injections were same...and everyone was looking for less injection. BUT, the main positive information in both phase II Clinical Studies was...the greater vision gain these patients had that continued over the weeks.
    Having greater vision gain is a much higher priority than having less injections. This study did show one less injection. "Patients treated with OHR-102 + Lucentis PRN required a mean of 2.0 Lucentis injections between weeks 10 and 38, compared with a mean of 3.3 Lucentis injections for the monotherapy group over the same time period."

    Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
    The positive results of this Phase II study demonstrates the role of OHR-102 combination therapy in RVO and represent an important milestone for the development of OHR-102 in the treatment of this disease," said Dr. Jason Slakter, Chief Medical Officer of Ohr. "This trial constitutes the second clinical study in a retinal vascular disorder which has shown a positive and clinically meaningful benefit in visual acuity using OHR-102 combination therapy versus an intravitreal anti-VEGF injection alone. The consistency of the efficacy data in this study, combined with the favorable safety profile of OHR-102, we believe warrants further study in a large controlled clinical trial."

    Sentiment: Strong Buy

  • Reply to

    Nice...got another chunk at 3.45.

    by pitwig Jul 14, 2015 9:33 AM
    surfer_bj surfer_bj Jul 14, 2015 6:58 PM Flag

    opt, Mark those words... because they'll soon disappear! Your words are meaningless...Still caught up in your egoistic thinking and are beginning to see the pressure with a 66% price jump with lite profit taking.
    Basically you can't see past your own nose about this News Report...Read it and Love it!

    Ohr Pharma announces positive results from its Phase II clinical study of OHR-102 to treat retinal vein occlusion. 7:31 AM ET 7/13/15

    Co announced positive final results from a Phase II investigator sponsored clinical trial of OHR-102 in patients with macular edema secondary to branch and central retinal vein occlusion (CRVO).
    The results demonstrated that, following an initial 10 week combination therapy treatment period, patients who continued to receive a combination of topical OHR-102 BID plus Lucentis achieved greater visual acuity gains than the control group who received Lucentis alone. At week 38, the mean gain in visual acuity from baseline for patients randomized (at week 10) to treatment with OHR-102 + Lucentis PRN was +27.8 letters compared with +23.3 for patients randomized to treatment with Lucentis plus PRN alone (control group), a clinically meaningful difference of +4.5 letters. Co stated: "The consistency of the efficacy data in this study, combined with the favorable safety profile of OHR-102, we believe warrants further study in a large controlled clinical trial."
    "These very promising final results demonstrate a clinically meaningful treatment effect of OHR-102 combination therapy for the treatment of macular edema secondary to retinal vein occlusion," said John Wroblewski, MD, principal investigator of this Phase II study. "The 38 week data confirm a positive and meaningful effect on both visual acuity and macular edema. Importantly, continued treatment with OHR-102 combination therapy for the full 38 weeks of the study resulted in further improvements in visual gains over those patients that only received combination therapy for the first 10 weeks of the study."

    This investigator-sponsored trial was designed to determine the effect of OHR-102 in eyes with macular edema secondary to retinal vein occlusion. The data presented at ASRS included the final analysis of patients that, following a 10 week initial combination treatment period, were randomized to receive either continued OHR-102 + LucentisPRN therapy or only Lucentis monotherapy PRN through week 38. After the initial combination therapy phase, the mean gain in visual acuity from week 10 to week 38 was +7.4 letters for patients who continued treatment with OHR-102 + Lucentis PRN compared with +3.1 letters in those receiving Lucentis PRN alone. Furthermore, at week 38, 80% of patients in the OHR-102 + Lucentis treated group had a gain in visual acuity, compared with 50% of patients treated with Lucentis alone. Additionally, at week 38, none of the patients in the OHR-102 + Lucentis treated group lost any vision. Patients treated with OHR-102 + Lucentis PRN required a mean of 2.0 Lucentis injections between weeks 10 and 38, compared with a mean of 3.3 Lucentis injections for the monotherapy group over the same time period.

    "The positive results of this Phase II study demonstrates the role of OHR-102 combination therapy in RVO and represent an important milestone for the development of OHR-102 in the treatment of this disease," said Dr. Jason Slakter, Chief Medical Officer of Ohr. "This trial constitutes the second clinical study in a retinal vascular disorder which has shown a positive and clinically meaningful benefit in visual acuity using OHR-102 combination therapy versus an intravitreal anti-VEGF injection alone. The consistency of the efficacy data in this study, combined with the favorable safety profile of OHR-102, we believe warrants further study in a large controlled clinical trial."

    Study Design

    The 38 week, investigator sponsored, Phase II clinical trial enrolled 20 treatment naïve patients with macular edema due to retinal vein occlusion. All patients received OHR-102 topically for the first 10 weeks of treatment, with two injections of Lucentis given at week 2 and week 6. The week 10 results were presented at ASRS 2014, and demonstrated that the combination of topical OHR-102 eye drops and intravitreal Lucentis led to a mean gain in visual acuity of 20.3 letters and resolution of the foveal edema in 95% of the patients. In the extension stage of the study (weeks 10 to 38), patients were randomized 1:1 at week 10 to either continue administering OHR-102 eye drops or discontinue drops for the remainder of the study. Retreatment with Lucentis injections were administered monthly as needed (PRN) through week 38 based on OCT criteria.

    Sentiment: Strong Buy

  • Reply to

    Pitwig

    by jkfatl_41 Jul 14, 2015 10:35 AM
    surfer_bj surfer_bj Jul 14, 2015 3:22 PM Flag

    Analyst are telling you OHRP is way undervalued while yesterdays news report tells you the phase II trial was overwhelmingly better than anyone expected and better than competitors. Yesterday's positive news report adds to the previous news. This tells me that wall street missed interpreted the last phase II news release and the reasons why FDA approved a Phase III trial that will be starting soon 2015.

    I view today as profit taking ....but expect better days ahead.

    Remember most Analyst tend to do much better research in analyzing a company including learning the newest updated information than the common investor.

    Sentiment: Strong Buy

  • Reply to

    ASRS - Dr. Wroblewski, See other MB at BH

    by djohnson8188 Jul 6, 2015 9:50 PM
    surfer_bj surfer_bj Jul 9, 2015 3:17 PM Flag

    And you among others, can determine the outcome and the effectiveness of the this study? Why, because of your great sense of smell. Shorting can become dangerous at some point. Yesterday was the best time to cover.
    The tide will turn....
    OHR and FDA backing their phase III trial to begin 2nd half of 2015, tells you that there is a very positive future for OHR to capitalize on its drug improving better vision with less treatments.

    "A character may not truly know who he is but he always knows who he thinks he is."

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jul 6, 2015 7:15 PM Flag

    There i a high prescribing likelihood among U.S. retinal specialists for target product profiles that are formulated as either an oral pill or an eye drop

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jul 6, 2015 7:04 PM Flag

    Interviewed experts highlight their desire for DME therapies which are patient administered, such as Ohr Pharmaceutical's squalamine eye drops and the emerging oral therapies, low-dose danazol (Optina; Ampio Pharmaceuticals) and Pfizer's PF-04634817.

    Sentiment: Strong Buy

  • surfer_bj surfer_bj Jul 6, 2015 6:47 PM Flag

    report entitled How Will the Complex Interplay Between Efficacy, Safety, and Delivery Impact Retinal Specialists' Preferences and Payer Acceptance of Current and Emerging Therapies?

    Perceptions of Eylea for DME: The anti-VEGF agent, Eylea (Regeneron/Bayer HealthCare/Santen), achieves the position of current clinical gold standard in Decision Resource Group's proprietary drug comparator model, owing to retinal specialists' perception of its superior efficacy and less frequent maintenance dosing for DME compared with the only other approved anti-VEGF for DME, Lucentis (Roche/Genentech/Novartis).

    -- Formulary inclusion and reimbursement: Surveyed U.S. managed care organization pharmacy directors are receptive to reimbursing novel DME therapies which offer improvements over current therapies on visual acuity, dosing frequency, or delivery profile, even indicating that they would accept a price premium over current branded DME therapies for therapies offering benefits on these attributes.

    Sentiment: Strong Buy

  • due to the burden on both patients and providers associated with monthly or semi-monthly anti-vascular endothelial growth factor (VEGF) injections, which are the current standard of care. The mid-stage compound, Allergan/Molecular Partners' abicipar pegol, which is in development for dosing every two to three months, could help lessen dosing frequency and U.S. retinal specialists anticipate prescribing the product to a median 20 percent of their diagnosed DME patients. Respondents also ascribe moderate to high unmet need for DME therapies which have a greater effect on improving visual acuity than current DME treatments (anti-VEGF agents and the long-acting corticosteroid implants, Allergan's Ozurdex and Alimera Sciences' Iluvien). In line with this finding, surveyed U.S. retinal specialists expect to prescribe Ohr Pharmaceutical's squalamine and Aerpio Therapeutics' AKB-9778, Phase II therapies in development for adjunctive use alongside anti-VEGF therapies, to 20 and 18 percent of their DME patients, respectively, in order to improve visual acuity beyond the level currently obtainable with anti-VEGF monotherapy.

    Sentiment: Strong Buy

  • Reply to

    Retina Society Meeting in Vienna

    by nvaa2 Jul 3, 2015 6:47 AM
    surfer_bj surfer_bj Jul 6, 2015 6:25 PM Flag

    Optimist_77 puts out smoke and screams whenever there is something positive in the works....It's called I know I'm right and everyone else is wrong. A name change to pessimistic_77 fits much better.

    Live and learn the hard way...while Retinal Specialists are is favor of OHRP drugs showing Greater Vision Gains: That's why your here with your pessimistic fits...

    Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies

    Sentiment: Strong Buy

  • BioBlast Pharma Receives Orphan Drug Designation From the European Commission for Cabaletta for the Treatment of Oculopharyngeal Muscular Dystrophy
    Israel, June 25, 2015 -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it has been granted Orphan Drug Designation by the European Commission for Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).

    BioBlast is starting a double-blind, placebo-controlled Phase 3 pivotal study across multiple clinical centers in the US and Canada in OPMD. The company recently announced positive clinical signals observed in its ongoing HOPEMD study.

    Cabaletta is a chemical chaperone that has been shown to prevent pathological aggregation of proteins within cells in several diseases associated with abnormal cellular-protein aggregation, including cell and animal models of Spinocerebellar Ataxia and other PolyA/PolyQ diseases, in addition to OPMD.

    "This Orphan Drug Designation lays the foundation for what we believe are very favorable conditions to address the needs of the many patients suffering from OPMD in Europe. It is yet another step in BioBlast's efforts to create and capture value from our research and clinical work," stated Colin Foster, President and Chief Executive Officer of BioBlast, who also noted that BioBlast has received Orphan Drug Designation for Cabaletta in OPMD from the FDA in the U.S.

    About Orphan Drug Designation

    Orphan Drug Designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, orphan drug designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access to the centralized authorization procedure.

    About Oculopharyngeal Muscular Dystrophy (OPMD)

    OPMD is a rare inherited myopathy characterized by dysphagia (difficulty in swallowing), the loss of muscle strength, and weakness in multiple parts of the body. Patients typically suffer from severe dysphagia, ptosis (eye lid drooping), tongue atrophy, proximal lower limb weakness, dysphonia (altered and weak voice), limitation in looking upward, facial muscle weakness and proximal upper limb weakness. The disease is most often diagnosed in the fifth-sixth decade of life and progresses throughout the patient's life. As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia. These last two are often the cause of death.

    There is no medical treatment or, to our knowledge, potential cure for OPMD. Current therapeutic strategies are confined to surgical interventions that have limited efficacy and need to be repeated.

    Sentiment: Strong Buy

ENZ
2.87+0.03(+1.06%)Aug 28 4:02 PMEDT